IDH1 and acute myeloid leukemia: Evidence from AML patients and preclinical models strongly suggests that IDH1 and IDH2 mutations are oncogenic drivers of AML and myelodysplastic syndrome and that targeting IDH mutant neomorphic activity in this context may provide therapeutic benefit by promoting the differentiation of malignant myeloid cells.